WO2008094001A1 - Cosmetic composition for preventing and improving baldness - Google Patents

Cosmetic composition for preventing and improving baldness Download PDF

Info

Publication number
WO2008094001A1
WO2008094001A1 PCT/KR2008/000577 KR2008000577W WO2008094001A1 WO 2008094001 A1 WO2008094001 A1 WO 2008094001A1 KR 2008000577 W KR2008000577 W KR 2008000577W WO 2008094001 A1 WO2008094001 A1 WO 2008094001A1
Authority
WO
WIPO (PCT)
Prior art keywords
add
extract
lotion
oil
cosmetic composition
Prior art date
Application number
PCT/KR2008/000577
Other languages
English (en)
French (fr)
Inventor
Hee Kyoung Kang
Jung Il Kang
Sang Cheol Kim
Jae Hee Hyun
Elvira Kim
Eun Sook Yoo
Jin Won Hyun
Moon Jae Cho
Deok Bae Park
Ki Ho Kim
Young Heui Kim
Original Assignee
Bioland Ltd.
Cheju National University Industry-Academic Cooperation Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioland Ltd., Cheju National University Industry-Academic Cooperation Foundation filed Critical Bioland Ltd.
Publication of WO2008094001A1 publication Critical patent/WO2008094001A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]

Definitions

  • the present invention relates to a cosmetic composition
  • a cosmetic composition comprising the extract of
  • Schisandra nigra Max. showing preventing activity of baldness and stimulating activity of hair growth.
  • Hair follicle a very complex organ, consists of an inner root sheath (IRS), outer root sheath (ORS), hair shaft, hair matrix cell (Paus et al., J. Invest. Dermatol., 113. pp523-532, 1999), and dermal papilla cell, which plays an important role in hair growth among various kinds of the cells forming the hair follicle (Ferraris et al., Exp. Cell Res., K), pp37-4 ⁇ 1997).
  • Hair follicle develops through the interaction between the mesenchymal cell and epithelial cell during an embryogenesis.
  • Normal hair growth consists of repeated three phases, i.e., anagen, catagen and telogen stages (Paus et al., N. Engl. J. Med., 341. pp491-497, 1999).
  • human hair has the longer growth period than any other animal hair or the other part hairs of the human body (anagen, 2-5 years; catagen, several days-several weeks; telogen, three months).
  • the cell consisting of hair follicle including the keratinocytic cell of matrix surrounding the dermal papilla proliferates and grows hair.
  • cytokines and growth factors are involved in the development and formation of hair follicle (Stenn et al., Physiol. Rev., 81, pp449-494, 2001); for example, tumor necrosis factor- ⁇ (TNF- ⁇ ), interleukin-l ⁇ (IL- l ⁇ ), interleukin-l ⁇ (IL- l ⁇ ), interferon- ⁇ (IFN- ⁇ ), fibroblast growth factor-5 (FGF5), hepatocyte growth factor (HGF), vascular epithelial growth factor (VEGF), insulin-like growth factor-I (IGF-I), insulin-like growth factor-II (IGF-II) and epithelial growth factor receptor (EGFR).
  • TNF- ⁇ tumor necrosis factor- ⁇
  • IL- l ⁇ interleukin-l ⁇
  • IFN- ⁇ interleukin-l ⁇
  • IFN- ⁇ interferon- ⁇
  • FGF5 fibroblast growth factor-5
  • HGF hepatocyte growth factor
  • TNF- ⁇ increases cell death in the matrix cell and inhibits the elongation of hair shaft (Soma et. al., J. Invest. Dermatol. , Ui, pp948-954, 1998).
  • IL-l ⁇ and IL- l ⁇ also inhibits the growth of the hair follicle (Mahe et al., Skin Pharmacol., 9£6), pp366-375, 1996; Xiong et al., J. Interferon Cytokine Res. , 12, ppl51-157, 1997).
  • the over-expression of IFN- ⁇ induces baldness (Carroll et al., J. Invest. Dermatol., 108(4).
  • FGF5 induces the telogen in hair follicle of rats (Hebert et al., Cell, 78, ppl017-1025, 1994 ⁇ while HGF (Jindo et al., J. Invest. Dermatol. , JjO, pp338-342, 1998) and VEGF (Yano et al., J. Clin. Invest., 107, pp409-417, 2001) promotes the growth of hair follicle. Also, IGF-I and IGF-II promotes the growth of hair follicle in a dose-dependent manner when incubating the hair follicle lacking insulin (Philpott et al., J. Invest.
  • FDA Fluorescence Activated Dermatase
  • 'Minoxidil' Buhl et al., J. Invest. Dermatol., 92(3). pp315-320, 1989
  • 'Finasteride' Van Neste et al., Br. J. Dermatol., 143(4). pp804-810, 2000.
  • TGF- ⁇ has been known as a cytokine to regulate various procedures, such as growth and differentiation (Massague et al., Cancer Surv., ⁇ 2, pp81-103, 1992). TGF- ⁇ is classified into 3 types in mammals, i.e., TGF- ⁇ l, TGF- ⁇ 2 and TGF- ⁇ 3 (Roberts et al., Heidelberg, Springer- Verlag., pp419-472, 1990), and recently the location of TGF- ⁇ expression of the 3 types in anagen and catagen hair follicle has been reported.
  • TGF- ⁇ l has been found at the hair cuticle and the connective tissue sheath of human anagen hair follicle, TGF- ⁇ 2, at the outer cellular layer of the outer root sheath of late anagen and TGF- ⁇ 3, at the keratinization-matrix cells (Soma et al., J. Invest. Dermatol., 118. pp993-997, 2002). Recently, among the isotypes, TGF- ⁇ 2 has been studied actively.
  • TGF- ⁇ 2 is seemed to have a key role in inducing the catagen of hair follicle and in- hibiting the hair follicle growth (Soma et al., J. Invest Dermatol., 118. pp993-997, 2002).
  • the inventors of the present invention evaluated the treating effect of the extract of Schisandra nigra Max on baldness by observing the preventing activity of baldness and stimulating activity of hair growth.
  • Schisandra nigra Max. is belonged to Schisandraceae consisting of 2 families and 22 species, for example, Schisandra nigra Max., Schisandra chinensis, Kadsura japonica, Schisandra nigra var., Schisandra viridicarpa and etc It is scarcely distributed at the height of 600-1,400 m of Mt.
  • Hanra located in Korea and the extract thereof has been known to contain schizandronic acid, schizandrolic acid, schizandronol, oplodiol, (+)-catechin-7- ⁇ -D-glucopyranoside, androsin, ⁇ -sitosteryl glucoside, schizandriside etc (Takani et al., Chem. Pharm. Bull., 27, pp 1422- 1425.1979).
  • the inventors of the present invention carried out various experiments to confirm the effect of the extract of Schisandra nigra Max. on hair growth, for example, the growth rate test using by vibrissa follicle, PCNA expression test and TGF- ⁇ 2 in rat hair follicle, and finally completed the present invention by confirming the potent activity of hair growth.
  • It is an object of the present invention to provide a cosmetic composition comprising the extract of Schisandra nigra Max., as an active ingredient in an effective amount to prevent baldness and stimulate hair growth.
  • the term 'extract' disclosed herein includes solvent selected from the group consisting of water, C i - C 4 lower alcohol and the mixture thereof, preferably, the mixture solvent with water and ethanol, more preferably 70 to 90% ethanol.
  • the term 'extract of Schisandra nigra Max.' disclosed herein comprises the flesh, peel, seed or root of Schisandra nigra Max.
  • the inventive extract of Schisandra nigra Max. can be prepared by the followings; one-day-dried Schisandra nigra Max. were cut and approximately 1 to 10-fold volume, preferably 1 to 3-fold volume of water, lower alcohols such as methanol, ethanol and the like or the mixtures thereof, preferably ethanol, more preferably 70 to 90% ethanol were added and extracted at the temperature range from 2O 0 C to 100 0 C, preferably 5O 0 C to 100 0 C for approximately 1 to 5 days, preferably 1 to 3 days; the upper layer is extracted by hot water, cold water, reflux extraction or ultra-sonication extraction; afterwards filtered, concentrated and dried to obtain the powdered extract of Schisandra nigra Max. of the present invention.
  • the inventive composition for preventing baldness and stimulating hair growth may comprise the above-described extract as 0.01-10%, preferably 0.1-8%, more preferably 0.5-5% by weight based on the total weight of the composition.
  • the other components may be a mixture of the ingredients of a conventional cosmetic composition well known in the art.
  • Cosmetic formulations containing above composition may be prepared in any form such as astringent, nutrient lotion, nutrient cream, massage cream, essence, pack, foundation, cleansing water, soap, treatment, beauty solution and the like.
  • the cosmetic composition of the present invention can comprises additional additives selected from the group consisting of water soluble vitamin, lipid soluble vitamin, peptide polymer, polysaccharide polymer, sphingolipid and sea- weed extract.
  • Preferable water soluble vitamins are any one which can be mixed with cosmetic, however, various vitamin such as vitamin B 1 , B 2 , B 6 , pyridoxine, pyridoxine HCl, vitamin B 12 , pantothenic add, nicotinic add, nicotinamide, folic add, vitamin C vitamin H etc, the salt thereof such as thiamin HCl salt, ascorbic add Na salt etc or their derivatives such as ascorbic add-2-phosphonic add Na salt, ascorbic add- 2-phosphonic add Mg salt are preferable and those can be obtained by conventional method such as microbial conversion method, purification method from the microbial cultivates, enzymatic method or chemical synthetic method.
  • various vitamin such as vitamin B 1 , B 2 , B 6 , pyridoxine, pyridoxine HCl, vitamin B 12 , pantothenic add, nicotinic add, nicotinamide, folic add, vitamin C vitamin H etc, the salt thereof such
  • Preferable lipid soluble vitamins are any one which can be mixed with cosmetic, however, various vitamin such as vitamin A, D 2 , D 3 , E (dl- ⁇ -tocopherol, d- ⁇ -tocopherol, d- ⁇ -tocopherol) and their derivatives such as palmitic add ascorbate, stearic add ascorbate, dipalmitic add ascorbate, acetic add- dl- ⁇ -tocopherol, nicotinic add dl- ⁇ -tocopherol vitamin E, dl-pantothenyl alcohol, D-pantothenyl alcohol, pan- tothenyl ethylether etc including the lipid soluble vitamin used in examples of present invention are preferable and those can be obtained by conventional method such as microbial conversion method, purification method from the microbial cultivates, enzymatic method or chemical synthetic method.
  • various vitamin such as vitamin A, D 2 , D 3 , E (dl- ⁇ -tocop
  • Preferable peptide polymers are any one which can be mixed with cosmetic, however, collagen, hydrolysable collagen, gelatin, elastin, hydrolysable gelatin, keratin etc including the peptide polymer used in examples of present invention are preferable.
  • Preferable polysaccharide polymers are any one which can be mixed with cosmetic, however, hydroxy ethyl cellulose, xanthin gum, hyaluronic add Na, chondroitin sulfate or their salt (Na salt etc) and the like are preferable.
  • chondroitin sulfate or the salt thereof etc can be used by being purified from mammal or fishes ordinarily.
  • sphingolipid are any one which can be mixed with cosmetic, however, ceramide, pit-sphingosin, sphingo-lipopolysaccharide and the like are preferable.
  • Sphingo-lipid can be obtained by being purified from mammal, fish, shellfish, yeast or plant etc in conventional method.
  • Preferable seaweed extract is any one which can be mixed with cosmetic, however, the extract of brown algae, red algae, green algae and the like or the purified car- rageenan, alginic add, arginic add Na, K isolated therefrom are preferable.
  • Algae extract can be obtained by being purified from seaweed in conventional method.
  • the cosmetic composition of the present invention may combine with other ingredients used in conventional cosmetic composition, if necessary, together with above described essential ingredient.
  • ingredients may comprise oil ingredient, humectants, emollients, surfactants, organic or inorganic dye, organic powder, ultraviolet ray absorbing agent, preservatives, antiseptics, antioxidants, plant extract, pH controller, alcohol, pigments, perfumes, refrigerants, blood drculator, antihidrotic, distilled water and etc
  • Preferable oil ingredients may comprise ester oil, hydrocarbon oil, silicone oil, fluoride oil, animal oil, plant oil and so on.
  • Preferable ester oil described above may comprise glyceryl tri-2-ethyl hexanoic add, cetyl 2-ethyl hexanoic add, isopropyl myristic add, butyl myristic add, isopropyl palmitic add, ethyl stearic add, octyl palmitic add, isocetyl isostearic add, butyl stearic add, ethyl linoleic add, isopropyl linoleic add, ethyl oleic add, isocetyl myristic add, isostearyl myristic add, isostearyl palmitic add, octyldodecyl myristic add, isocetyl isostearic add, diethyl sebasic add, isopropyl adipic add, isoalkyl neo- petanoic add, glyceryl
  • Preferable hydrocarbon oil described above may comprise squalene, liquid paraffin, ⁇ -olefin oligomer, isoparaffin, ceresin, paraffin, liquid isoparaffin, polybuden, micro- crystalline wax, vaselin and the like.
  • Preferable silicone oil may comprise polymethylsilicone, methylphenylsilicone, methylcyclopolysiloxane, octamethylpolysiloxane, decamethylpolysiloxane, dode- camethylcyclosiloxane, dimethyl siloxane-methyl cetyloxysiloxan copolymer, dimethyl siloxane-methyl stealoxysiloxane copolymer, alkyl modified silicone oil, amino modified silicone oil and the like.
  • Preferable fluoride oil can comprise perfluoropolyether and the like.
  • Preferable animal or plant oil can comprise avocado oil, almond oil, olive oil, sesame oil, rice husk oil, safflower oil, soy-bean oil, corn oil, rape oil, amygdalin oil, palm kernel oil, palm oil, pimaja oil, sunflower oil, fruite seed oil, cotton seed oil, cooonut palm oil cucui nut oil, wheat embryo bud oil, rice embryo bud oil, sia butter, evening- primrose oil, marker daymia nut oil, medo home oil, egg yolk oil, lanolin, hempseed oil, mink oil, orange ruppy oil, hohoba oil, carnawa wax, liquid lanolin, solid pimaja wax and the like.
  • Preferable humectants can comprise water-soluble low molecular humectants, lipophilic low molecular humectants, water-soluble polymer and lipid soluble polymer.
  • preferable water soluble low molecular humectants can comprise cerin, glutamine, sorbitol, mannitol, pyrrolidone-carboxylic add Na, gljcerin, propylene glyjol, 1,3-butylene glyx>l, ethylene gljcol, polyethylene glyx>l (polymerization index. >2 ⁇ polypropylene glyx>l (polymerization index. >2 ⁇ lactic add, lactate salt and the like.
  • Preferable lipid soluble low molecular humectants can comprise cholesterol, cholesteryl ester and the like.
  • Preferable water soluble polymer can comprise carboxy vinyl polymer, poly asparaginic add salt, tragacanth, xanthin gum, HMC (hydroxy methyl celluose), HBC (hydroxy ethyl celluose), HPC (hydroxy propyl celluose), carboxymethylcellulose, water soluble chitin, chitosan, dextrin and the like.
  • Preferable lipid soluble polymer can comprise polyvinylpyrrolidone-eicocene copolymer, polyvinylpyrrolidone -hexadecene copolymer, nitrocellulose, dextrin fatty add ester, silicone polymer and the like.
  • Preferable emollients can comprise long chain acyl glutamic add cholesteryl ester, cholesteryl hydroxy stearic add, 12-hydroxy stearic add, rogic add, lanolin fatty add cholesteryl ester and the like.
  • Preferable surfactant can comprise nonionic surfactants, anionic surfactants, cationic surfactants, ambivalent surfactants and the like.
  • preferable non-ionic surfactants can comprise self-emulsified monostearic add gljcerin, propylene glyx>l fatty add ester, gljcerin fatty add ester, polygljcerin fatty add ester, sorbitan fatty add ester, polyoxyethylene (POE) sorbitan fatty add ester, POE sorbitan fatty add ester, POE gljcerin fatty add ester, POE alkyl ether, POE fatty add ester, POE solid pimaja oil, POE pimaja oil, POE-POP copolymer, POE-POP alkyl ether, polyether modified silicone, lauric add alkanol amide, alkyl amine oxide, hydrogen addition soybean phospholipid and the like.
  • POE polyoxyethylene
  • Preferable anionic surfactants can comprise fatty add soap, a-acyl sulfonic add salt, alkyl sulfonic add salt, alkyl ally sulfonic add, alkyl naphthalene sulfonic add salt, alkyl sulfonic add salt, POE alkylether sulfate salt, alkyl amide sulfate salt, alkyl phosphate salt, POE alkyl phosphate salt, alkylamide phosphate salt, alkyloylalkyl taurine salt, N-acyl-amino add salt, POE alkyl ether carboxylic add salt, alkyl sulfo succinic aid salt, alkyl sulfo- acetic add salt, acylated hydroly sable collagen peptide salt, perfluoro alkyl phosphate ester and the like.
  • Preferable cationic surfactant can comprise alkyl trimethyl ammonium chloride, stearyl trimethyl ammonium chloride, stearyl trimethyl ammonium bromide, setoste- aryltrimethyl ammonium chloride, distearyl dimethyl ammonium chloride, stearyl dimethyl benzyl ammonium chloride, vehenyltrimethyl ammonium bromide, ben- zalkonium chloride, diethylamino ethyl amide stearic add, dimethylaminopropyl amide stearic add, lanolin derivatives quaternary ammonium and the like.
  • Preferable ambivalent surfactants can comprise carboxy betaine type, amide betaine type, hydroxy sulfo betaine type, phosphobetaine type, aminocarboxylic add, imidazoline derivatives type, amide amine type and the like.
  • Preferable organic and inorganic dyes can comprise silidc add, anhydrous silidc add, magnesium silidc add, talc, ceracyte, mica, caolin, bengala, clay, bentonite, titan film mica, oxy chlorine bismuth, zirconium oxide, magnesium oxide, zinc oxide, titan oxide, aluminium oxide, calcium sulfate, barium sulfate, magnesium sulfate, calcium carbonate, magnesium carbonate, ferrous oxide, chromium oxide, chromium hydroxide, calamine, carbon black and the complex thereof as an inorganic dyes; polyamide, polyester, polypropylene, polystyrene, polyurethane, vinyl resin, urea resin, phenol resin, fluoride resin, silicone resin, acryl resin, melamine resin, epoxy resin, poljcarbonated resin, divinyl benzene-styrene copolymer, silk powder, cellulose, Q pigment yellow, Q pigment orange as an organic dyes;
  • Preferable organic powder can comprise metal soap such as calcium stearate; alkyl phosphonate metal salt such as sodium zinc cetylic add, zinc laurylic add, caldum laurylic add; acylamino add polyvalent metal salt such as caldum N- lauroyl- ⁇ -alanine, zinc N-lauroyl- ⁇ -alanine, caldum N-lauroyl-glydne etc; amide sulfonic add polyvalent metal salt such as caldum N-lauroyl-taurine, caldum N- palmitoyl-taurine; N-acyl basic amino add such as N ⁇ -lauroyl-L-lysine, N ⁇ - palmitoyl-lysine, N ⁇ -palmitoyl ornitine, N ⁇ -lauroly arginine, hardened lanolin fatty add acyl arginine and the like; N-acylpolypeptide such as N-lauroylgljcyl g
  • Preferable ultraviolet absorbing agents can comprise paraaminobenzoic add, paraa- monoethyl benzoate, paraamino amyl benzoate, paraamino octyl benzoate, ethyl- enegljcol salicylate, phenyl salicylate, octyl salicylate, benzyl salicylate, butylphenyl salicylate, homomentyl salicylate, benzyl dnnamic add, paramethoxy 2-ethoxy ethyl dnnamic add, paramethoxy octyl dnnamic add, diparamethoxy mono-2-ethylhexane glyceryl dnnamic add, paramethoxy isopropyl dnnamic add, diisopropyl-diisopropyl dnnamate ester mixture, urokanic add, ethyl uroka
  • Preferable preservatives can comprise hinokitiol, trichloric add, trichlorohydroxydi- phenylether, chlorohexidine glucuronate, phenoxyethanol, resordne, isopropyl- methylphenol, azulene, salicylic add, zinc pilithione, bezalconium HCl, photo- sensitizer 301, mononitroguaiacol Na, undecylenic add etc
  • Preferable antioxidants can comprise butylhydroxyanisole, propyl gallate, ellisorbate and the like.
  • Preferable pH controller can comprise citric add, sodium citrate, malic acid, sodium malate, fumaric acid, sodium fumaric acid, succinic acid, sodium succinic acid, sodium hydroxide, sodium hydrogen phosphate and the like.
  • Preferable alcohol can comprise cetyl alcohol etc
  • the cosmetic composition of the present invention can be modified as a solution, emulsion, cohesive mixture etc
  • cosmetic formulation of the present invention may be prepared in any form well-known in the art for example, skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisture lotion, nutrient lotion, massage lotion, nutrient cream, moisture cream, hand cream, foundation, essence, nutrient essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, body solution, body cleanser and the like.
  • the paste, cream or gel formulation of the present invention may use lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder etc as a cosmetic carrier and further add chlorofluorohydrocarbon, propan/butane or dimethyl ether as an expellant.
  • the solution of emulsion formulation of the present invention may use solvent, solubilizer, or emulsifier such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, glycerol fatty ester, PEG or sorbitan fatty ester etc
  • the suspension formulation of the present invention may use appropriate carrier, for example, liquid dilution such as water, ethanol or PEG; emulsifier such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, or poly- oxyethylene sorbitane ester; and microcrystalline cellulose, aluminum meta hydroxide, bentonite, agar or traganth etc
  • the surfactant comprising cleansing formulation of the present invention may use fatty alcohol sulfate, fatty alcohol ether sulfate, sulfosuc ⁇ nic add monoester, icetionate, imidazolinum derivative, methyl taurate, sarocynate, fatty add amide ethyl sulfate, alkyl amido betaine, fatty alcohol, fatty add gljceride, fatty add diethanol amide, plant oil, linolic add, or ethoxylated glycerol fatty add ester etc
  • Inventive compounds of the present invention have no toxidty and adverse effect therefore can be used with safe.
  • the present invention relates to a cosmetic composition
  • a cosmetic composition comprising the extract of
  • Schisandra nigra Max. showing preventing activity of baldness and stimulating activity of hair growth.
  • Fig. 1 shows the effect of inventive extract on PCNA expression of the hair follicle
  • Fig. 2 shows the effect of inventive extract on TGF- ⁇ 2 expression of the hair follicle.
  • Example 1 Prepaprtion of the extract of Schisandra nigra Max.
  • 1 Kg of Schisandra nigra Max. (Jeju-do) was washed with tap water, dried for one day, cut and mixed with 3 L of 85% (v/v) ethanol. The solution was extracted for 3 days with reflux extraction and the residue was filtered. The filtrate was concentrated with rotary evaporator (Evaporator, JP/N-N, EYELA) at 35 0 C for 4 hours, and then dried for 48 hours to obtain powdered extract of Schisandra nigra Max. (67.65 g).
  • rotary evaporator Evaporator, JP/N-N, EYELA
  • the powder was dissolved in DMSO (Dimethyl sulfoxide, Sigma, MO, USA) to use as samples in the following Experimental Examples.
  • the extract was stored in -2O 0 C and diluted to the extent that the final concentration reached to 0.1% DMSO in each experiment.
  • the vibrissa follicle were placed in a Petri dish containing the E/P buffer solution and incubated at 37 0 C, in 5% CO 2 incubator for 2 hours.
  • 500 j ⁇ of William E medium (Gibco Inc, NY, USA) containing 2 mM L-glutamine (Gibco Inc, NY, USA), 10 ⁇ g/ ⁇ d of insulin (Sigma MO, USA), 50 nM hydrocortisone (Sigma MO, USA) and 100 units/ mi of penicillin- 100 ⁇ g/m# of streptomydn were added to each well of 24- well plate and one vibrissa follicle was placed to each well. The well was further incubated at 37 0 C, in 5% CO 2 incubator.
  • the media was exchanged in every 3 days and treated with the test sample at the concentration of 5, 10, 20 and 50 ⁇ g/m#, and minoxidil sulfate (Sigma, USA) as positive controls at the concentration of 0.1, 1 and 10 ⁇ M respectively to compare with each other.
  • the media was exchanged in every 3 days and treated with the inventive extract at the concentration of 20 ⁇ glr ⁇ , and minoxidil sulfate (Sigma, USA) as a positive control at the concentration of 10 ⁇ M.
  • the vibrissa follicle was fixed for 24 hours with 4% paraformaldehyde and washed with 20% sucrose twice. Then, the vibrissa follicle was dehydrated, and solidified to form a parafilm block through transparency or parafilm penetration process using by an automatic tissue processor (Leica, Germany).
  • the parafilm blocks were sliced in the width of 4 ⁇ m, attached to a silane coating slide (Muto Chemicals, Japan) and dried.
  • the slides were treated with xylene for 3 times to remove parafilm, hydrated and immunohistochemistry was performed thereto according to ABC Staining Kit (Santa cruz biotechnology, Inc, USA). 1% Hydrogen peroxide (H 2 O 2 ) was treated to inhibit the action of endogenous enzyme, and 1.5% blocking serum was treated for an hour to prevent nonspecific binding with primary antibody.
  • HRP Hydrogen peroxide
  • rabbit anti-PCNA antibody Santa Cruz Biotechnology, Inc, USA
  • diluted to 1: 200 was used as a primary antibody. After the treatment of primary antibody overnight, the well was washed with PBS for 3 times, and treated with anti-rabbit IgG for 30 minutes as the secondary antibody.
  • HRP horseradish peroxidase enzyme reagent
  • the media was exchanged in every 3 days and treated with the inventive extract at the concentration of 20 ⁇ g/m-6, and minoxidil sulfate (Sigma, USA) as a positive control at the concentration of 10 ⁇ M.
  • the vibrissa follicle was fixed for 24 hours with 4% paraformaldehyde and washed with 20% sucrose twice. Then, the vibrissa follicle was dehydrated, and solidified to form a parafilm block through transparency or parafilm penetration process using by an automatic tissue processor (Leica, Germany).
  • the parafilm blocks were sliced in the width of 4 ⁇ m, attached to a silane coating slide (Muto Chemicals, Japan) and dried.
  • the slides were treated with xylene for 3 times to remove parafilm, hydrated and im- munohistochemistray was performed according to ABC Staining Kit (Santa cruz biotechnology, Inc, USA). 1% Hydrogen peroxide (H 2 O 2 ) was treated to inhibit the action of endogenous enzyme, and 1.5% blocking serum was treated for an hour to prevent nonspecific binding with primary antibody.
  • H 2 O 2 Hydrogen peroxide
  • rabbit anti-TGF- ⁇ 2 antibody (Santa Cruz Biotechnology, Inc, USA) diluted to 1: 200 was used as a primary antibody. After the treatment of primary antibody overnight, the well was washed with PBS for 3 times, and treated with the secondary antibody, anti-rabbit IgG for 30 minutes.
  • HRP horseradish peroxidase enzyme reagent
  • TGF- ⁇ 2 expression was not observed on the day of isolation of the vibrissa follicle, and the group treated with 20 ⁇ g/md, of the inventive extract at the 7 * day in the bulb matrix region surrounding the dermal papilla of the hair follicle did not also showed TGF- ⁇ 2 expression.
  • the group treated with 10 ⁇ M minoxidil sulfate at the 7 th day also showed no expression of TGF- ⁇ 2. Therefore, it has been confirmed that the inventive extract prepared in Example 1 inhibited the TGF- ⁇ 2 expression relevant to the progression from anagen to catagen and it showed potent stimulating activity of hair growth by acting on anagen phase ( See Fig. 2).
  • Skin preparation was prepared by dissolving the active components according to conventional lotion preparation method.
  • lotion preparation was prepared by dissolving the active components according to conventional lotion preparation method.
  • Cream preparation was prepared by dissolving the active components according to conventional cream preparation method. [142]
  • Pack preparation was prepared by dissolving the active components according to conventional pack preparation method. [157]
  • Beauty solution preparation was prepared by dissolving the active components according to conventional beauty solution preparation method [167]
  • the extract of Schisandra nigra Max showed potent preventing activity of baldness and stimulating activity of hair growth being confirmed by several experiments such as the growth rate test using by vibrissa follicle, PCNA and TGF- ⁇ 2 expression test in rat hair follicle. Accordingly, the inventive extract can be used as a cosmetic composition for the treatment of baldness and stimulation of hair growth.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Cosmetics (AREA)
PCT/KR2008/000577 2007-01-30 2008-01-30 Cosmetic composition for preventing and improving baldness WO2008094001A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2007-0009205 2007-01-30
KR1020070009205A KR100841920B1 (ko) 2007-01-30 2007-01-30 탈모 방지 및 발모 개선 효과를 갖는 화장료 조성물

Publications (1)

Publication Number Publication Date
WO2008094001A1 true WO2008094001A1 (en) 2008-08-07

Family

ID=39674256

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2008/000577 WO2008094001A1 (en) 2007-01-30 2008-01-30 Cosmetic composition for preventing and improving baldness

Country Status (2)

Country Link
KR (1) KR100841920B1 (ko)
WO (1) WO2008094001A1 (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015075542A1 (en) * 2013-11-25 2015-05-28 Nuova Fapam S.R.L. Remedy for halting hair loss

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102298460B1 (ko) 2021-01-27 2021-09-08 주식회사 에피바이오텍 콜라겐 유전자 또는 단백질을 포함하는 탈모의 예방 또는 개선용 조성물
KR102576659B1 (ko) * 2021-10-15 2023-09-08 주식회사 하람 흑오미자 추출물을 유효성분으로 함유하는 피부상태 개선용 조성물
KR102576662B1 (ko) * 2021-10-15 2023-09-08 주식회사 하람 흑오미자 추출물을 유효성분으로 함유하는 환경호르몬에 의해 손상된 피부상태 개선용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10310532A (ja) * 1997-05-09 1998-11-24 Dai Ichi Seiyaku Co Ltd テストステロン−５α−レダクターゼ阻害剤
KR20030016150A (ko) * 2001-08-20 2003-02-26 최기남 모발촉진제
JP2005119996A (ja) * 2003-10-15 2005-05-12 Sato Pharmaceutical Co Ltd 育毛剤
KR100636846B1 (ko) * 2006-03-21 2006-10-19 최형근 천연한방 모발 생장촉진 조성물 및 그 제조방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10310532A (ja) * 1997-05-09 1998-11-24 Dai Ichi Seiyaku Co Ltd テストステロン−５α−レダクターゼ阻害剤
KR20030016150A (ko) * 2001-08-20 2003-02-26 최기남 모발촉진제
JP2005119996A (ja) * 2003-10-15 2005-05-12 Sato Pharmaceutical Co Ltd 育毛剤
KR100636846B1 (ko) * 2006-03-21 2006-10-19 최형근 천연한방 모발 생장촉진 조성물 및 그 제조방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015075542A1 (en) * 2013-11-25 2015-05-28 Nuova Fapam S.R.L. Remedy for halting hair loss

Also Published As

Publication number Publication date
KR100841920B1 (ko) 2008-06-27

Similar Documents

Publication Publication Date Title
JP4199743B2 (ja) ニキビ用皮膚化粧料
EP2987536A1 (en) Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles
KR101017709B1 (ko) 인삼 등의 복합 생약 추출물을 함유하는 탈모 방지, 비듬 생성 억제 및 발모 촉진효과를 갖는 화장료 조성물
KR20110108687A (ko) 천연 원료 추출물을 포함하는 미백제 및 이를 포함하는 화장료 조성물
JP2007126368A (ja) 抗老化剤、コラゲナーゼ阻害剤および抗酸化剤
US12102707B2 (en) Skin care composition
US9592183B2 (en) Inhibitor of endothelin action and skin-whitening agent
JPH0717845A (ja) 皮膚外用剤
WO2008094001A1 (en) Cosmetic composition for preventing and improving baldness
KR101800956B1 (ko) 파이토스핑고신과 효모추출물을 유효성분으로 포함하는 탈모방지 및 발모촉진용 조성물
JP2003176213A (ja) 育毛剤
JP2011219402A (ja) Ｐｏｍｃ産生抑制剤
US20160213605A1 (en) A composition comprising an extract of combined herbs consisting of Acanthopanax koreanum Nakai and Crinum asiaticum var. japonicum showing preventing activity of baldness and stimulating activity of hair growth
JP2015124188A (ja) 皮脂合成抑制剤
KR100975819B1 (ko) 후박 추출물 또는 이로부터 분리된 ４―０―메틸호노키올을함유하는 탈모 방지 및 모발 생장 촉진용 조성물
JP2018138533A (ja) 毛髪化粧料
JP6267957B2 (ja) 皮脂合成抑制剤
KR101873159B1 (ko) 탈모방지 및 발모촉진 효과를 갖는 조성물
JPH1029924A (ja) 抗老化剤
KR101658333B1 (ko) Bca 복합 발효물 및 모낭줄기세포 추출물을 함유하는 탈모방지 및 모발성장 조성물
JP7032852B2 (ja) 毛髪化粧料
EP3162375A1 (en) Whitening composition comprising scutellaria alpina extract
KR100931528B1 (ko) 꽈리 추출물을 유효성분으로 함유하는 피부미백용조성물
JP2020176064A (ja) 育毛用組成物
EP3127548B1 (en) Composition comprising extract of artemisia umbelliformis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08712246

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08712246

Country of ref document: EP

Kind code of ref document: A1